[Treatment of toxic hepatitis in COVID-19 patients].

Igor Maev R I Shaburov A I Pavlov A I Molodova A G Karakozov S P Kazakov E G Lebedeva A F Ivolgin M N Eremin O B Levchenko

Published in: Terapevticheskii arkhiv (2023)

The use of drugs with hepatoprotective effect in the form of monotherapy in groups 1 (UDCA) and 2 (ademethionine) showed a low therapeutic effect with positive dynamics of clinical and laboratory indicators of toxic hepatitis activity. The use of combined treatment in group 3 (UDCA and ademethionine) demonstrated the maximum therapeutic effect, pronounced positive dynamics in the form of normalization of clinical and laboratory indicators of toxic hepatitis activity.

Keyphrases

sars cov
combination therapy